ImageneBio, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $800.0K | $3.5M | $9.2M | $15.6M | $31.0M | $9.2M |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $28.5M | $32.1M | $59.7M | $64.3M | $47.1M | $44.8M |
| SG&A Expense | $20.7M | $8.4M | $24.9M | $22.2M | $18.0M | $8.9M |
| Operating Income | $-48.5M | $-37.0M | $-75.4M | $-70.9M | $-34.1M | $-44.5M |
| Operating Margin | -6,056.4% | -1,057.1% | -823.3% | -454.0% | -110.2% | -484.2% |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | $-45.7M | $-36.6M | $-68.3M | $-68.8M | — | — |
| Income Tax Expense | $-350.0K | $13.0K | $-162.0K | $0 | $0 | — |
| Net Income | $-45.3M | $-36.6M | $-68.2M | $-68.8M | $-34.1M | $-44.3M |
| Net Margin | -5,668.6% | -1,044.8% | -744.2% | -440.3% | -110.1% | -481.4% |
| EPS (Basic) | $-9.64 | $-22.10 | $-1.63 | $-1.90 | $-1.22 | $-16.00 |
| EPS (Diluted) | $-9.64 | $-22.10 | $-1.63 | $-1.90 | $-1.22 | $-16.00 |
| Shares Outstanding (Basic) | 4.9M | 1.2M | 41.7M | 36.2M | 28.0M | 3.1M |
| Shares Outstanding (Diluted) | 4.9M | 48.3M | 41.7M | 36.2M | 28.0M | 3.1M |
| Dividends Per Share | — | — | — | — | — | — |